COMPANY RESEARCHWave Life Sciences is a U.S.-domiciled biotechnology company developing therapeutic technologies that act on RNA. Its research includes RNA editing, gene silencing and other oligonucleotide-based approaches designed to alter disease-related biological pathways. The company has interests in rare genetic disorders and selected metabolic and neurologic diseases. Wave is headquartered operationally in Cambridge, Massachusetts, and its common stock trades on Nasdaq under WVE. Following a 2026 redomiciliation, its Delaware parent succeeded an earlier Singapore-incorporated issuer without creating a second independent listing.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Wave Life Sciences is a U.S.-domiciled biotechnology company developing therapeutic technologies that act on RNA. Its research includes RNA editing, gene silencing and other oligonucleotide-based approaches designed to alter disease-related biological pathways. The company has interests in rare genetic disorders and selected metabolic and neurologic diseases. Wave is headquartered operationally in Cambridge, Massachusetts, and its common stock trades on Nasdaq under WVE. Following a 2026 redomiciliation, its Delaware parent succeeded an earlier Singapore-incorporated issuer without creating a second independent listing.
Nasdaq: WVE
RNA editing · RNA interference · oligonucleotides
rare diseases · metabolic disease · neurology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Wave develops RNA-targeting medicines using RNA interference and RNA editing approaches. Its October 27, 2026 update describes WVE-007 as an investigational GalNAc-siRNA and WVE-006 as an investigational RNA-editing oligonucleotide. These are distinct modalities, not mRNA products.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| WVE-007 | INHBE · Obesity | IIa期；2026-10-27Disclosed | Human/approved evidence; see original source for scope |
| WVE-006 | SERPINA1 · Alpha-1 antitrypsin deficiency | Ib/IIa期；注册试验规划中 | Human/approved evidence; see original source for scope |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 1 / 1 related items
Wave's quarterly update describes planning for a registrational WVE-006 RNA-editing study in AATD and ongoing WVE-007 siRNA Phase 2a work. The company also reports FDA support for its LC-MS assay in the planned WVE-006 program. Regulatory feedback and trial plans do not constitute marketing approval or comparative efficacy evidence.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.